MAR 15, 2018 6:59 PM PDT

Cannabis compound shows promise for severe epilepsy

WRITTEN BY: Invisiverse

For the first time, a form of medicinal cannabis has been shown to reduce—and even stop—seizures in some children with a severe form of epilepsy.

The children suffer from Dravet syndrome, a severe epilepsy that begins in infancy with drug-resistant seizures and a high mortality rate.

The seizures of five percent of the children stopped after they were treated with cannabidiol, a non-psychoactive form of cannabis. Overall, 43 percent of children with the syndrome had a 50 percent reduction in seizure frequency.

Known as CBD, cannabidiol is a natural compound found in cannabis seeds, stalks, and flowers that does not have the psychoactive properties of tetrahydrocannabinol, or THC.

“It’s the first scientific evidence that cannabidiol works,” says Ingrid Scheffer, professor of pediatric neurology at the University of Melbourne. “There have been anecdotal reports in the past, and people with firm beliefs that it works in epilepsy, but this is the first time it’s been proven.”

For the study, published in the New England Journal of Medicine, 120 children and young adults across the US and Europe received cannabidiol or a placebo, in addition to standard anti-epileptic treatment. The research took place as part of the Cannabidiol in Dravet Syndrome Study Group, and was a randomized, double-blind, and placebo-controlled trial.

Researchers measured seizure frequency over a 14-week treatment period. The findings show that the average frequency of convulsive seizures per month decreased from 12.4 to 5.9 among those children on cannabidiol, compared with a decrease from 14.9 to 14.1 among those on the placebo.

“I am delighted that we finally have high-level evidence that cannabidiol is effective for uncontrolled seizures in Dravet syndrome,” Scheffer says.

“If you can render any child or adult seizure free, that’s huge. It could contribute to stopping any further deterioration, or help development in a positive sense.”

Researchers asked caregivers to fill out the Global Impression of Change questionnaire—a seven-category system rating the scale of change in a patient. The results show that the patient’s overall condition improved by at least one category in 62 percent of the cannabidiol group, compared with only 34 percent of the placebo group.

Although the frequency of total seizures of all types was significantly reduced with cannabidiol, there was no significant reduction in non-convulsive seizures. But five percent of patients taking cannabidiol became seizure-free, compared with none of the placebo group.

“Many people who take part in trials like this are desperate to try something new. They’ve exhausted other options,” Scheffer says. “Five percent seizure-free is not 100 percent or 75 percent, but it’s reassuring to see that improvement. For these 5 percent of kids in the trial, it’s huge.

“Sadly this is not a panacea; it’s not going to cure these children. But it does give cause to be optimistic about further research for its use. It also raises a lot of questions, not just in terms of the treatment of epilepsy, but where else it could be applied medicinally. Cannabidiol is likely to be an important addition to our group of anti-epileptic tools.

There is a downside to the findings: side effects were more frequent in the cannabidiol group,  including diarrhea, vomiting, fatigue, decreased appetite, increased body temperature, drowsiness. and abnormal liver-function tests.

Worldwide, it’s estimated that around 1 percent of the population has epilepsy—about 65 million people globally. Dravet syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in infancy. Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), it affects around 1 in almost 16,000 people.

Current treatment options are limited, and the associated seizures are particularly difficult because they are frequent, unpredictable, life-threatening, and not controlled by many anti-epileptic drugs.

“The next question is whether cannabidiol is effective in other forms of epilepsy,” Scheffer says. “It is great that there are trials already underway of cannabidiol in other groups of patients with epilepsy.”

 

This article was originally posted on futurity.org

About the Author
You May Also Like
OCT 01, 2020
Cell & Molecular Biology
Signaling Waves Help Guide Cells to Heal Wounds
OCT 01, 2020
Signaling Waves Help Guide Cells to Heal Wounds
During development and throughout our lives, cells have to 'know' where to go to form the right structures and properly ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 11, 2020
Microbiology
Getting Closer to a Vaccine for Flaviviruses
OCT 11, 2020
Getting Closer to a Vaccine for Flaviviruses
Flaviviruses like dengue, West Nile, Zika, Japanese Encephalitis, and yellow fever infect over 400 million people a year ...
OCT 24, 2020
Genetics & Genomics
Cord Blood Samples Reveal More About the Genetics of Autism
OCT 24, 2020
Cord Blood Samples Reveal More About the Genetics of Autism
The activity of genes in our genome is controlled by many factors, one of which are chemical tags or structural changes ...
Loading Comments...